Systematix Sees Dr Reddy’s Stock Rising 10–15% if Biosimilar Wins December Approval
Systematix analyst Vishal Manchanda says Dr Reddy’s stock could advance 10–15% if a major drug approval materialises in December 2026. The company has resolved semaglutide manufacturing challenges and is ready to resume supply.